• Phone: +1-631-791-1145
  • Email: sales@imarcgroup.com

North America HIV Drugs Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024

The North America HIV drugs market reached a value of US$ 9.8 Billion in 2018. HIV, which stands for human immunodeficiency virus, is a type of retrovirus which damages the immune system by destroying the white blood cells, or CD4 cells, that help in fighting against infection. Antiretroviral therapy, or ART, is known as the method used for treating the HIV infection with HIV drugs. ART patients must follow the HIV regimen every day in which they have to consume a prescribed combination of HIV drugs. This therapy method does not cure HIV but, instead, helps people with the infection to lead longer and healthier lives. HIV drugs help in preventing the multiplication of HIV which provides a possible recovery chance to the patients. These drugs make the immune system strong enough to resist certain infections and other HIV-related complications.

North America HIV drugs market is currently being driven by several factors. The region currently represents one of the strongest economies leading to a well-established healthcare system. This acts as one of the key factors which is fostering the growth of the HIV drugs market in the region. In addition to this, the US and Canadian governments are consistently extending their helping-hand by investing funds on the research and development of safer and potent HIV drugs. Moreover, higher diagnosis and treatment rate coupled with a surge in the adoption of advanced treatments act as another factor which is facilitating the growth of the HIV drugs market in North America. Apart from this, Antiretroviral drugs have played a major role in improving survival rates and the quality of life of HIV patients. These drugs help the immune system to keep the levels of the virus to a minimum level and prevent infections, leading to the prolonged life expectancy in patients. Antiretrovirals, when taken in the right combination can result in immune reconstitution, restore health, and prevent the development of AIDS and AIDS-related conditions. The progressive reduction in mortality and gains in the life expectancy are also a result of the improvements in therapy over the past few years. Additionally, antiretroviral drugs help in reducing the risk of HIV transmission. HIV treatment helps in reducing the level of the virus in the blood and other bodily fluids such as semen and vaginal and rectal fluids to imperceptible levels. It also helps in controlling the replication of the virus in the body.

IMARC’s new report provides a deep insight into the North America HIV drugs market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. This report is a must-read for drug manufacturers, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the North America HIV drugs market in any manner.


Report Scope:

  • North America HIV Drugs Market
     
  • Key Regions Analysed
    • United States
    • Canada
       
  • Analysis for Each Country
     
  • Market by Drug Class
    • Nucleoside Reverse Transcriptase Inhibitors
    • Multi-Class Combination Products
    • Protease Inhibitors
    • HIV Integrase Strand Transfer Inhibitors
    • Non-Nucleoside Reverse Transcriptase Inhibitors
    • Entry Inhibitors — CCR5 Co-Receptor Antagonist
    • Others
       
  • Market by Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Others
       
  • Value Chain Analysis
  • Key Drivers and Challenges
  • Porters Five Forces Analysis
  • Competitive Landscape
    • Competitive Structure
    • Key Player Profiles


Key Questions Answered in This Report:

  • How has the North America HIV drugs market performed so far and how will it perform in the coming years?
  • What are the key regions in the North America HIV drugs market?
  • What is the breakup of the North America HIV drugs market on the basis of drug class?
  • What is the breakup of the North America HIV drugs market on the basis of distribution channel?
  • What are the various stages in the value chain of the North America HIV drugs industry?
  • What are the key driving factors and challenges in the North America HIV drugs industry?
  • What is the structure of the North America HIV drugs industry and who are the key players?
  • What is the degree of competition in the North America HIV drugs industry?
  • What are the profit margins in the North America HIV drugs industry?


Report Coverage:

  • Base Year Considered: 2018
  • Historical Data Coverage: 2013-2018
  • Market Forecast: 2019-2024
  • Currency: US$
  • Geography Covered: North America, United States and Canada
  • Segments Covered: Drug Class and Distribution Channel.


Report Customization: Although IMARC has tried to cover everything in the North America HIV drugs market landscape, we believe that every stakeholder may have their own specific needs. In view of this, we provide up to 20-man hours of free customization for each report.

1    Preface
2    Scope and Methodology

    2.1    Objectives of the Study
    2.2    Stakeholders
    2.3    Data Sources
        2.3.1    Primary Sources
        2.3.2    Secondary Sources
    2.4    Market Estimation
        2.4.1    Bottom-Up Approach
        2.4.2    Top-Down Approach
    2.5    Forecasting Methodology
3    Executive Summary
4    Introduction

    4.1    Overview
    4.2    Key Industry Trends
5    Global HIV Drugs Market
    5.1    Market Performance
    5.2    Market Breakup by Drug Class
    5.3    Market Breakup by Distribution Channel 
    5.4    Market Breakup by Region 
    5.5    Market Forecast 
6    North America HIV Drugs Market
    6.1    Market Performance
    6.2    Market Forecast 
7    North America HIV Drugs Market: Breakup by Drug Class 
    7.1    Nucleoside Reverse Transcriptase Inhibitors
    7.2    Multi-Class Combination Products
    7.3    Protease Inhibitors
    7.4    HIV Integrase Strand Transfer Inhibitors
    7.5    Non-Nucleoside Reverse Transcriptase Inhibitors
    7.6    Entry Inhibitors — CCR5 Co-Receptor Antagonist
    7.7    Others
8    North America HIV Drugs Market: Breakup by Distribution Channel 
    8.1    Hospital Pharmacies
    8.2    Retail Pharmacies
    8.3    Online Pharmacies
    8.4    Others
9    North America HIV Drugs Market: Breakup by Country 
    9.1   United States
     9.1.1    Historical Market Trends
     9.1.2    Market Breakup by Drug Class
     9.1.3    Market Breakup by Distribution Channel
     9.1.4    Market Forecast
    9.2   Canada
     9.2.1    Historical Market Trends
     9.2.2    Market Breakup by Drug Class
     9.2.3    Market Breakup by Distribution Channel
     9.2.4    Market Forecast
10    SWOT Analysis 
    10.1    Overview 
    10.2    Strengths
    10.3    Weaknesses 
    10.4    Opportunities
    10.5    Threats
11    Value Chain Analysis 
    11.1    Overview
    11.2    Research and Development
    11.3    Raw Material Procurement
    11.4    Manufacturing
    11.5    Marketing
    11.6    Distribution
    11.7    End-Use
12    Porter’s Five Forces Analysis 
    12.1     Overview
    12.2     Bargaining Power of Buyers
    12.3     Bargaining Power of Suppliers
    12.4     Degree of Rivalry
    12.5     Threat of New Entrants
    12.6     Threat of Substitutes
13    Price Analysis 
14    Competitive Landscape

    14.1    Market Structure
    14.2    Key Players
    14.3    Profiles of Key Players

List of Figures

Figure 1: Global: HIV Drugs Market: Sales Value (in Billion US$), 2013-2018
Figure 2: Global: HIV Drugs Market: Breakup by Drug Class (in %), 2018
Figure 3: Global: HIV Drugs Market: Breakup by Distribution Channel (in %), 2018
Figure 4: Global: HIV Drugs Market: Breakup by Region (in %), 2018
Figure 5: Global: HIV Drugs Market Forecast: Sales Value (in Billion US$), 2019-2024
Figure 6: North America: HIV Drugs Market: Sales Value (in Million US$), 2013-2018
Figure 7: North America: HIV Drugs Market Forecast: Sales Value (in Million US$), 2019-2024
Figure 8: North America: HIV Drugs Market: Breakup by Drug Class (in %), 2018
Figure 9: North America: HIV Drugs (Nucleoside Reverse Transcriptase Inhibitors) Market: Sales Value (in Million US$), 2013 & 2018
Figure 10: North America: HIV Drugs (Nucleoside Reverse Transcriptase Inhibitors) Market Forecast: Sales Value (in Million US$), 2019-2024
Figure 11: North America: HIV Drugs (Multi-Class Combination Products) Market: Sales Value (in Million US$), 2013 & 2018
Figure 12: North America: HIV Drugs (Multi-Class Combination Products) Market Forecast: Sales Value (in Million US$), 2019-2024
Figure 13: North America: HIV Drugs (Protease Inhibitors) Market: Sales Value (in Million US$), 2013 & 2018
Figure 14: North America: HIV Drugs (Protease Inhibitors) Market Forecast: Sales Value (in Million US$), 2019-2024
Figure 15: North America: HIV Drugs (HIV Integrase Strand Transfer Inhibitors) Market: Sales Value (in Million US$), 2013 & 2018
Figure 16: North America: HIV Drugs (HIV Integrase Strand Transfer Inhibitors) Market Forecast: Sales Value (in Million US$), 2019-2024
Figure 17: North America: HIV Drugs (Non-Nucleoside Reverse Transcriptase Inhibitors) Market: Sales Value (in Million US$), 2013 & 2018
Figure 18: North America: HIV Drugs (Non-Nucleoside Reverse Transcriptase Inhibitors) Market Forecast: Sales Value (in Million US$), 2019-2024
Figure 19: North America: HIV Drugs (Entry Inhibitors — CCR5 Co-Receptor Antagonist) Market: Sales Value (in Million US$), 2013 & 2018
Figure 20: North America: HIV Drugs (Entry Inhibitors — CCR5 Co-Receptor Antagonist) Market Forecast: Sales Value (in Million US$), 2019-2024
Figure 21: North America: HIV Drugs (Other Drugs Classes) Market: Sales Value (in Million US$), 2013 & 2018
Figure 22: North America: HIV Drugs (Other Drugs Classes) Market Forecast: Sales Value (in Million US$), 2019-2024
Figure 23: North America: HIV Drugs Market: Breakup by Distribution Channel (in %), 2018
Figure 24: North America: HIV Drugs Market: Sales Through Supermarkets and Hypermarkets (in Million US$), 2013 & 2018
Figure 25: North America: HIV Drugs Market Forecast: Sales Through Supermarkets and Hypermarkets (in Million US$), 2019-2024
Figure 26: North America: HIV Drugs Market: Sales Through Convenience and Grocery Stores (in Million US$), 2013 & 2018
Figure 27: North America: HIV Drugs Market Forecast: Sales Through Convenience and Grocery Stores (in Million US$), 2019-2024
Figure 28: North America: HIV Drugs Market: Sales Through Online Stores (in Million US$), 2013 & 2018
Figure 29: North America: HIV Drugs Market Forecast: Sales Through Online Stores (in Million US$), 2019-2024
Figure 30: North America: HIV Drugs Market: Sales Through Other Distribution Channels (in Million US$), 2013 & 2018
Figure 31: North America: HIV Drugs Market Forecast: Sales Through Other Distribution Channels (in Million US$), 2019-2024
Figure 32: North America: HIV Drugs Market: Breakup by Country (in %), 2018
Figure 33: United States: HIV Drugs Market: Sales Value (in Million US$), 2013-2018
Figure 34: United States: HIV Drugs Market: Breakup by Drug Class (in %), 2018
Figure 35: United States: HIV Drugs Market: Breakup by Distribution Channel (in %), 2018
Figure 36: United States: HIV Drugs Market Forecast: Sales Value (in Million US$), 2019-2024
Figure 37: Canada: HIV Drugs Market: Sales Value (in Million US$), 2013-2018
Figure 38: Canada: HIV Drugs Market: Breakup by Drug Class (in %), 2018
Figure 39: Canada: HIV Drugs Market: Breakup by Distribution Channel (in %), 2018
Figure 40: Canada: HIV Drugs Market Forecast: Sales Value (in Million US$), 2019-2024
Figure 41: North America: HIV Drugs Industry: SWOT Analysis
Figure 42: North America: HIV Drugs Industry: Value Chain Analysis
Figure 43: North America: HIV Drugs Industry: Porter’s Five Forces Analysis

List of Tables

Table 1: North America: HIV Drugs Market: Key Industry Highlights, 2018 and 2024
Table 2: North America: HIV Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2019-2024
Table 3: North America: HIV Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2019-2024
Table 4: North America: HIV Drugs Market Forecast: Breakup by Country (in Million US$), 2019-2024
Table 5: North America: HIV Drugs Market: Competitive Structure
Table 6: North America: HIV Drugs Market: Key Players

Note: We value your privacy and will never rent or sell your email address. Privacy policy

Purchase Options




$ 2499

REACH OUT TO US

Call us on

( US: +1-631-791-1145 )
( UK: +44-702-409-7331 )
( India: +91-120-433-0800 )


Drop us an email at

sales@imarcgroup.com

Social Links